drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous, humanized anti-CD19 chimeric antigen receptor (CAR) T-cell therapy using a humanized scFv against CD19 linked to CD3ζ signaling and a 4-1BB costimulatory domain to target and eliminate CD19-positive B-lineage malignant cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a humanized anti‑CD19 CAR containing CD3ζ signaling and 4‑1BB costimulation. Upon binding CD19 on B‑lineage malignant cells, the CAR activates and co‑stimulates T cells to proliferate, persist, and mediate cytotoxic killing of CD19‑positive tumor cells.
drug_name
huCART19
nct_id_drug_ref
NCT05674175